leader in biofilm dispersion 生物膜分解的领导者 - nai 500.pdf

Leader in Biofilm Dispersion 生物膜分解的領導者 GCFF Toronto Conference 2015 2015年國際金融投資博覽會多倫多會展 Mark Ahrens-Townsend President CEO 總裁兼首席執行官 September 26,2015/2015年9月26 日 FORWARD LOOKING INFORMATION 前瞻性陳述 This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue RD activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s ongoing filings with the Canadian and U.S. securities authorities for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update these forward-looking statements. KANE BIOTECH INC. KANE BIOTECH INC.公司簡介 • Leading the advancement of technologies and products that break up and inhibit biofilms for use in the animal and human health markets 帶領推動用于動物和人類健康市場的生物膜分解和抑制技術及産品進步 • Strong patent portfolio of biofilm dispersion technologies and research collaborations with leading research groups (US Army, University of Toronto, Texas Tech University, Baylor University,…) 生物膜分解技術領域的强大專利組合，幷與主要研究組織展開研究合作（美國軍隊、多倫多 大學、德州理工大學和貝勒大學） • Three highly effective and safe co